SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Darakhshan J. Haleem, 5-HT1A receptor-dependent control of nigrostriatal dopamine neurotransmission in the pharmacotherapy of Parkinson’s disease and schizophrenia, Behavioural Pharmacology, 2015, 26, 45

    CrossRef

  2. 2
    H. Iderberg, A.C. McCreary, M.A. Varney, M.A. Cenci, A. Newman-Tancredi, Activity of serotonin 5-HT1A receptor ‘biased agonists’ in rat models of Parkinson's disease and l-DOPA-induced dyskinesia, Neuropharmacology, 2015, 93, 52

    CrossRef

  3. 3
    Camino Fidalgo, Wai Kin D Ko, Elisabetta Tronci, Qin Li, Roberto Stancampiano, Qin Chuan, Erwan Bezard, Manolo Carta, Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson’s disease, Neuroscience, 2015,

    CrossRef

  4. 4
    Fernando Eduardo Padovan-Neto, Roberta Cavalcanti-Kiwiatkoviski, Ruither Oliveira Gomes Carolino, Janete Anselmo-Franci, Elaine Del Bel, Effects of prolonged neuronal nitric oxide synthase inhibition on the development and expression of l-DOPA-induced dyskinesia in 6-OHDA-lesioned rats, Neuropharmacology, 2015, 89, 87

    CrossRef

  5. 5
    Sabeena Sharma, Samardeep Singh, Vishavdeep Sharma, Vijay Pal Singh, Rahul Deshmukh, Neurobiology of l-DOPA induced dyskinesia and the novel therapeutic strategies, Biomedicine & Pharmacotherapy, 2015, 70, 283

    CrossRef

  6. 6
    Eugene V. Mosharov, Anders Borgkvist, David Sulzer, Presynaptic effects of levodopa and their possible role in dyskinesia, Movement Disorders, 2015, 30, 1
  7. 7
    S. Mazzucchi, D. Frosini, A. Ripoli, V. Nicoletti, G. Linsalata, U. Bonuccelli, R. Ceravolo, Serotonergic antidepressant drugs and L-dopa-induced dyskinesias in Parkinson's disease, Acta Neurologica Scandinavica, 2015, 131, 3
  8. 8
    Perdita Cheshire, Scott Ayton, Kelly L. Bertram, Helen Ling, Abi Li, Catriona McLean, Glenda M. Halliday, Sean S. O'Sullivan, Tamas Revesz, David I. Finkelstein, Elsdon Storey, David R. Williams, Serotonergic markers in Parkinson's disease and levodopa-induced dyskinesias, Movement Disorders, 2015, 30, 5
  9. 9
    D Lindenbach, N Palumbo, C Y Ostock, N Vilceus, M M Conti, C Bishop, Side effect profile of 5-HT treatments for Parkinson's disease and L-DOPA-induced dyskinesia in rats, British Journal of Pharmacology, 2015, 172, 1
  10. 10
    U. Keber, M. Klietz, T. Carlsson, W.H. Oertel, E. Weihe, M.K.-H. Schäfer, G.U. Höglinger, C. Depboylu, Striatal tyrosine hydroxylase-positive neurons are associated with l-DOPA-induced dyskinesia in hemiparkinsonian mice, Neuroscience, 2015,

    CrossRef

  11. 11
    Veronica Francardo, Hanna Iderberg, Hanna Lindgren, M. Angela Cenci, Movement Disorders, 2015,

    CrossRef

  12. 12
    Melissa M. Conti, Corinne Y. Ostock, David Lindenbach, Adam A. Goldenberg, Elias Kampton, Rich Dell'isola, Aaron C. Katzman, Christopher Bishop, Effects of prolonged selective serotonin reuptake inhibition on the development and expression of l-DOPA-induced dyskinesia in hemi-parkinsonian rats, Neuropharmacology, 2014, 77, 1

    CrossRef

  13. 13
    Cristina Miguelez, Teresa Morera-Herreras, Maria Torrecilla, Jose A. Ruiz-Ortega, Luisa Ugedo, Interaction between the 5-HT system and the basal ganglia: functional implication and therapeutic perspective in Parkinson's disease, Frontiers in Neural Circuits, 2014, 8,

    CrossRef

  14. 14
    I. G. Silkis, Mutual influence of serotonin and dopamine on the functioning of the dorsal striatum and motor activity (hypothetical mechanism), Neurochemical Journal, 2014, 8, 3, 149

    CrossRef

  15. 15
    Eva Schaeffer, Andrea Pilotto, Daniela Berg, Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease, CNS Drugs, 2014, 28, 12, 1155

    CrossRef

  16. 16
    M. Angela Cenci, Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications, Frontiers in Neurology, 2014, 5,

    CrossRef

  17. 17
    N. Nevalainen, S. af Bjerkén, G.A. Gerhardt, I. Strömberg, Serotonergic nerve fibers in l-DOPA-derived dopamine release and dyskinesia, Neuroscience, 2014, 260, 73

    CrossRef

  18. 18
    Manolo Carta, Elisabetta Tronci, Serotonin System Implication in l-DOPA-Induced Dyskinesia: From Animal Models to Clinical Investigations, Frontiers in Neurology, 2014, 5,

    CrossRef

  19. 19
    Emma Thornton, Mark Macquarie Hassall, Frances Corrigan, Robert Vink, The NK1 receptor antagonist N-acetyl-l-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model, Parkinsonism & Related Disorders, 2014, 20, 5, 508

    CrossRef

  20. 20
    Elisabetta Tronci, Manolo Carta, 5-HT1 receptor agonists for the treatment of L-DOPA-induced dyskinesia: From animal models to clinical investigation, Basal Ganglia, 2013, 3, 1, 9

    CrossRef

  21. 21
    Elisabetta Tronci, Carlo Lisci, Roberto Stancampiano, Camino Fidalgo, Maria Collu, Paola Devoto, Manolo Carta, 5-Hydroxy-tryptophan for the treatment of l-DOPA-induced dyskinesia in the rat Parkinson's disease model, Neurobiology of Disease, 2013, 60, 108

    CrossRef

  22. 22
    Erwan Bézard, Ana Muñoz, Elisabetta Tronci, Elsa Y. Pioli, Qin Li, Gregory Porras, Anders Björklund, Manolo Carta, Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia, Neuroscience Research, 2013, 77, 4, 242

    CrossRef

  23. 23
    Kristin B. Dupre, Corinne Y. Ostock, Jessica A. George, Karen L. Eskow Jaunarajs, Cara M. Hueston, Christopher Bishop, Effects of 5-HT1AReceptor Stimulation on D1 Receptor Agonist-Induced Striatonigral Activity and Dyskinesia in Hemiparkinsonian Rats, ACS Chemical Neuroscience, 2013, 4, 5, 747

    CrossRef

  24. 24
    Maryka Quik, Archana Mallela, Matthew Chin, J. Michael McIntosh, Xiomara A. Perez, Tanuja Bordia, Nicotine-mediated improvement in l-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function, Neurobiology of Disease, 2013, 50, 30

    CrossRef

  25. 25
    Nirmal Bhide, David Lindenbach, Margaret A. Surrena, Adam A. Goldenberg, Christopher Bishop, S. Paul Berger, Melanie A. Paquette, The effects of BMY-14802 against l-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian rat, Psychopharmacology, 2013, 227, 3, 533

    CrossRef

  26. 26
    Philippe Huot, Susan H. Fox, The serotonergic system in motor and non-motor manifestations of Parkinson’s disease, Experimental Brain Research, 2013, 230, 4, 463

    CrossRef

  27. 27
    Maryka Quik, Carla Campos, Tanuja Bordia, Jon-Paul Strachan, Jenny Zhang, J. Michael McIntosh, Sharon Letchworth, Kristen Jordan, α4β2 nicotinic receptors play a role in the nAChR-mediated decline in l-dopa-induced dyskinesias in parkinsonian rats, Neuropharmacology, 2013, 71, 191

    CrossRef

  28. 28
    Elisabetta Tronci, Eunju Shin, Anders Björklund, Manolo Carta, Amphetamine-induced rotation and l-DOPA-induced dyskinesia in the rat 6-OHDA model: A correlation study, Neuroscience Research, 2012, 73, 2, 168

    CrossRef

  29. 29
    Melanie A. Paquette, Alex A. Martinez, Teresa Macheda, Charles K. Meshul, Steven W. Johnson, S. Paul Berger, Andrea Giuffrida, Anti-dyskinetic mechanisms of amantadine and dextromethorphan in the 6-OHDA rat model of Parkinson’s disease: role of NMDA vs. 5-HT1A receptors, European Journal of Neuroscience, 2012, 36, 9
  30. 30
    Golnasim Riahi, Marc Morissette, Daniel Lévesque, Claude Rouillard, Pershia Samadi, Martin Parent, Thérèse Di Paolo, Effect of chronic l-DOPA treatment on 5-HT1A receptors in parkinsonian monkey brain, Neurochemistry International, 2012, 61, 7, 1160

    CrossRef

  31. 31
    Sylvia Navailles, Philippe De Deurwaerdère, Imbalanced Dopaminergic Transmission Mediated by Serotonergic Neurons in L-DOPA-Induced Dyskinesia, Parkinson's Disease, 2012, 2012, 1

    CrossRef

  32. 32
    Philippe Huot, Tom H. Johnston, Naomi P. Visanji, Tayyeba Darr, Donna Pires, Lili-Naz Hazrati, Jonathan M. Brotchie, Susan H. Fox, Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's disease, Movement Disorders, 2012, 27, 6
  33. 33
    K.L. Eskow Jaunarajs, J.A. George, C. Bishop, L-DOPA-induced dysregulation of extrastriatal dopamine and serotonin and affective symptoms in a bilateral rat model of Parkinson’s disease, Neuroscience, 2012, 218, 243

    CrossRef

  34. 34
    Paul J. Tuite, Silvia Mangia, Andrew E. Tyan, Michael K. Lee, Michael Garwood, Shalom Michaeli, Magnetization transfer and adiabatic R1ρ MRI in the brainstem of Parkinson’s disease, Parkinsonism & Related Disorders, 2012, 18, 5, 623

    CrossRef

  35. 35
    Eunju Shin, Elisabetta Tronci, Manolo Carta, Role of Serotonin Neurons in L-DOPA- and Graft-Induced Dyskinesia in a Rat Model of Parkinson's Disease, Parkinson's Disease, 2012, 2012, 1

    CrossRef

  36. 36
    Eunju Shin, Joanna Garcia, Christian Winkler, Anders Björklund, Manolo Carta, Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease, Neurobiology of Disease, 2012, 47, 3, 393

    CrossRef

  37. 37
    Perdita A. Cheshire, David R. Williams, Serotonergic involvement in levodopa-induced dyskinesias in Parkinson’s disease, Journal of Clinical Neuroscience, 2012, 19, 3, 343

    CrossRef

  38. 38
    Adjmal Nahimi, Mette Høltzermann, Anne M. Landau, Mette Simonsen, Steen Jakobsen, Aage Kristian Olsen Alstrup, Kim Vang, Arne Møller, Gregers Wegener, Albert Gjedde, Doris J. Doudet, Serotonergic modulation of receptor occupancy in rats treated with l-DOPA after unilateral 6-OHDA lesioning, Journal of Neurochemistry, 2012, 120, 5
  39. 39
    Christopher Bishop, Jessica A. George, William Buchta, Adam A. Goldenberg, Mohamed Mohamed, Sando O. Dickinson, Satie Eissa, Karen L. Eskow Jaunarajs, Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats, European Journal of Neuroscience, 2012, 36, 6
  40. 40
    P. De Deurwaerdère, S. Navailles, What can we expect from the serotonergic side of l-DOPA?, Revue Neurologique, 2012, 168, 12, 927

    CrossRef

  41. 41
    Philippe Huot, Jonathan M. Brotchie, 5-HT1A receptor stimulation and L-DOPA-induced dyskinesia in Parkinson's disease: Bridging the gap between serotonergic and glutamatergic mechanisms, Experimental Neurology, 2011, 231, 2, 195

    CrossRef

  42. 42
    M. Carta, E. Bezard, Contribution of pre-synaptic mechanisms to l-DOPA-induced dyskinesia, Neuroscience, 2011, 198, 245

    CrossRef

  43. 43
    Nina Nevalainen, Sara af Bjerkén, Martin Lundblad, Greg A. Gerhardt, Ingrid Strömberg, Dopamine release from serotonergic nerve fibers is reduced in L-DOPA-induced dyskinesia, Journal of Neurochemistry, 2011, 118, 1
  44. 44
    Manfred Gerlach, Jürgen Beck, Peter Riederer, Maarten van den Buuse, Flibanserin attenuates l-DOPA-sensitized contraversive circling in the unilaterally 6-hydroxydopamine-lesioned rat model of Parkinson’s disease, Journal of Neural Transmission, 2011, 118, 12, 1727

    CrossRef

  45. 45
    Kristin B. Dupre, Corinne Y. Ostock, Karen L. Eskow Jaunarajs, Thomas Button, Lisa M. Savage, William Wolf, Christopher Bishop, Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats, Experimental Neurology, 2011, 229, 2, 288

    CrossRef

  46. 46
    Karen L. Eskow Jaunarajs, Mariana Angoa-Perez, Donald M. Kuhn, Christopher Bishop, Potential mechanisms underlying anxiety and depression in Parkinson's disease: Consequences of l-DOPA treatment, Neuroscience & Biobehavioral Reviews, 2011, 35, 3, 556

    CrossRef

  47. 47
    Manfred Gerlach, Gerd D. Bartoszyk, Peter Riederer, Olivia Dean, Maarten van den Buuse, Role of dopamine D3 and serotonin 5-HT1A receptors in l-DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson’s disease, Journal of Neural Transmission, 2011, 118, 12, 1733

    CrossRef

  48. 48
    Corinne Y. Ostock, Kristin B. Dupre, Karen L. Eskow Jaunarajs, Hannah Walters, Jessica George, David Krolewski, Paul D. Walker, Christopher Bishop, Role of the primary motor cortex in l-DOPA-induced dyskinesia and its modulation by 5-HT1A receptor stimulation, Neuropharmacology, 2011, 61, 4, 753

    CrossRef

  49. 49
    Tiantian Ren, Xinxin Yang, Na Wu, Yunpeng Cai, Zhenguo Liu, Weien Yuan, Sustained-release formulation of levodopa methyl ester/benserazide for prolonged suppressing dyskinesia expression in 6-OHDA-leisoned rats, Neuroscience Letters, 2011, 502, 2, 117

    CrossRef

  50. 50
    Philippe Huot, Susan H. Fox, Jonathan M. Brotchie, The serotonergic system in Parkinson's disease, Progress in Neurobiology, 2011, 95, 2, 163

    CrossRef

  51. 51
    Karen L. Eskow Jaunarajs, Kristin B. Dupre, Corinne Y. Ostock, Thomas Button, Terrence Deak, Christopher Bishop, Behavioral and neurochemical effects of chronic L-DOPA treatment on nonmotor sequelae in the hemiparkinsonian rat, Behavioural Pharmacology, 2010, 21, 7, 627

    CrossRef

  52. 52
    Mark J. Millan, From the cell to the clinic: A comparative review of the partial D2/D3 receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease, Pharmacology & Therapeutics, 2010, 128, 2, 229

    CrossRef

  53. 53
    Xinxin Yang, Weien Yuan, Tianan Ren, Lu Song, Na Wu, Zhenguo Liu, Levodopa/benserazide-loaded biodegradable microspheres reduce dyskinesia in rats, NeuroReport, 2010, 21, 12, 837

    CrossRef

  54. 54
    Manolo Carta, Thomas Carlsson, Ana Muñoz, Deniz Kirik, Anders Björklund, Role of serotonin neurons in the induction of levodopa- and graft-induced dyskinesias in Parkinson's disease, Movement Disorders, 2010, 25, S1
  55. 55
    Thomas V. Wiecki, Michael J. Frank, Recent Advances in Parkinson’s Disease: Basic Research, 2010,

    CrossRef

  56. 56
    Karen L. Eskow Jaunarajs, Kristin B. Dupre, Aimee Steiniger, Anna Klioueva, Alexander Moore, Catherine Kelly, Christopher Bishop, Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia, NeuroReport, 2009, 20, 14, 1265

    CrossRef